XML 26 R17.htm IDEA: XBRL DOCUMENT v3.6.0.2
Going Concern (Details Narrative)
9 Months Ended
Dec. 02, 2016
USD ($)
shares
Dec. 02, 2016
GBP (£)
shares
Nov. 16, 2016
USD ($)
Oct. 14, 2016
USD ($)
Jul. 12, 2016
USD ($)
Mar. 23, 2016
USD ($)
Mar. 21, 2016
USD ($)
Dec. 28, 2015
USD ($)
$ / shares
shares
Apr. 30, 2012
USD ($)
Jan. 31, 2017
USD ($)
$ / shares
shares
Jan. 31, 2016
USD ($)
Jan. 31, 2017
EUR (€)
Oct. 19, 2016
$ / shares
Jul. 07, 2016
USD ($)
Apr. 30, 2016
USD ($)
Jan. 22, 2016
USD ($)
Jun. 19, 2015
USD ($)
Working capital deficit                   $ 94,374              
Accumulated deficit                   2,978,719         $ 3,089,331    
Debt conversion price per share | $ / shares                         $ 0.01017        
Repayment of debt           $ 33,500     $ 1,500                
Impairment loss recognized                   $ (2,499)            
Investments                   1              
Business combination consideration transferred                   2,696,105              
Assumption of certain liabilities                   $ 2,179,833              
Euro [Member] | Venn Life Sciences [Member]                                  
Cash reserves and a bank loan facility | €                       € 1,000,000          
Mercuriali Ltd [Member]                                  
Advance from related party                               $ 90,000  
Integumen Limited [Member]                                  
Reserve for interim costs     $ 30,000 $ 25,000                          
Number of ordinary shares received | shares 2,632,868 2,632,868               2,179,833              
Due from related parties                   $ 28,747              
Post completion costs                   48,698              
Impairment loss recognized                   $ 2,179,832              
Business combination consideration transferred $ 3,840,525                                
Assumption of certain liabilities 416,272                                
Prepayment of note $ 100,000                                
Percentage of accrued interest per annum                   80.00%   80.00%          
Asset purchase agreement, description                   The APA provided that 80 per cent of the Consideration Shares should be issued on completion of the APA and the remaining 20 per cent (subject to an adjustment depending on the value of the assumed liabilities) should be issued within 30 days of Admission of Integumen to AIM.              
Integumen Limited [Member] | GBP [Member]                                  
Business acquisition share price per share | $ / shares                   $ 1              
Business combination consideration transferred | £   £ 3,030,000                              
Assumption of certain liabilities | £   320,209                              
Prepayment of note | £   £ 76,923                              
Integumen Limited [Member] | Option Agreement [Member]                                  
Proceeds from loans         $ 100,000                        
Secured promissory note                           $ 100,000      
Vis Vires Group Inc [Member]                                  
Value of convertible promissory note issued                                 $ 43,000
Conversion of promissory note into shares, value               $ 12,000                  
Debt conversion price per share | $ / shares               $ 0.0017                  
Conversion of promissory note shares | shares               7,058,824                  
Mercuriali [Member] | Loan Agreement (Amendment 5) [Member] | Minimum [Member]                                  
Proceeds from loans             $ 90,000                    
Mercuriali [Member] | Loan Agreement (Amendment 5) [Member] | Maximum [Member]                                  
Proceeds from loans             $ 150,000